Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $15.57 Average PT from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received an average recommendation of "Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $15.57.

A number of research firms have commented on FULC. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, May 14th. Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics in a research report on Wednesday, March 13th. They set an "outperform" rating and a $14.00 price objective for the company. Oppenheimer reduced their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, May 14th. The Goldman Sachs Group raised shares of Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $6.00 to $15.00 in a research report on Monday, May 13th. Finally, Piper Sandler boosted their target price on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an "overweight" rating in a research report on Wednesday, February 28th.

Fulcrum Therapeutics Stock Up 4.7 %

Shares of NASDAQ:FULC traded up $0.30 during midday trading on Friday, hitting $6.68. The stock had a trading volume of 1,372,144 shares, compared to its average volume of 542,621. Fulcrum Therapeutics has a 12 month low of $3.03 and a 12 month high of $13.70. The business's 50-day simple moving average is $7.50 and its 200-day simple moving average is $7.98. The company has a market cap of $415.16 million, a P/E ratio of -4.17 and a beta of 2.34.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. As a group, equities analysts predict that Fulcrum Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of FULC. Citigroup Inc. raised its stake in Fulcrum Therapeutics by 1,028.5% in the third quarter. Citigroup Inc. now owns 89,189 shares of the company's stock valued at $396,000 after purchasing an additional 81,286 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Fulcrum Therapeutics in the third quarter valued at about $268,000. FMR LLC raised its stake in Fulcrum Therapeutics by 7.6% in the third quarter. FMR LLC now owns 5,975,416 shares of the company's stock valued at $26,531,000 after purchasing an additional 421,676 shares in the last quarter. Algert Global LLC acquired a new position in Fulcrum Therapeutics in the third quarter valued at about $138,000. Finally, Brown Wealth Management LLC acquired a new position in Fulcrum Therapeutics in the third quarter valued at about $111,000. Institutional investors and hedge funds own 89.83% of the company's stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.